Amer completed his M.Sc in Pharmacology at Bradford University, Postgraduate studies in Medical Sciences at University College Hospital, Diploma in Biological Sciences from Salford University and Postgraduate Certificate in Clinical Research from Surrey University. A…more ›

Dr Arellano is a medical doctor who is currently working as Vice-President, Head of Safety and Pharmacovigilance at GSK Biologicals Belgium. He completed his M.D. degree from the University of Madrid, Spain, followed by training in Pharmacoepidemiology from Mc Gill Uni…more ›

Simon obtained his PhD from the University of Liverpool and gained 17 years experience in drug development within the contract research industry (Huntingdon Life Sciences). Originally with a background in Drug Metabolism and Pharmacokinetics, Simon spent many years mana…more ›

Vicki Edwards qualified as a pharmacist in 1981 and started her career in hospital pharmacy. In 1983 she specialised in Drug Information Services and moved to Kuwait to set up and run the first National Drug Information Centre. The Centre became a showpiece for the Mi…more ›

Alastair Fowkes has over 20 years experience in pharmacovigilance and has worked extensively in the area of safety systems for the last 10. He has worked on or led three safety system implementation projects and two ICH E2B implementation projects. He has been working…more ›

E. Stewart Geary, M.D, has worked at Eisai since 1996 in pharmacovigilance, clinical safety and regulatory science. He is currently a member of the CIOMS IX Working Group on Medicinal Product Risk Management, the Executive Committees of the Japanese Association of Pharm…more ›

Jean-Marie Heim, MD is currently Medical Director, Safety Assessment, responsible for the global cardio-vascular and metabolic mature BMS portfolio, handling over 20 drugs. He is a trained physician from the Brussels University specialized in Clinical Toxicology (thesis…more ›

Noha Kassem gained a Ph.D in Pharmaceutics in 1990 from King’s Collage, University of London. She joined Eli Lilly in 1990 as a Research scientist; she then assumed several responsibilities including Head of Clinical trial manufacturing and supplies as well as worked as…more ›

• Medical doctor 1987 • 7 years of experience within toxicology • 16 years of experience within Pharmacovigilance • 2½ years at the Danish Medical Agency • 1½ years at H. Lundbeck • 12 years at Novo Nordisk • 11 years in HQ Global Safety • 1 year in NNI (NN US…more ›

Dr Geneviève Lapeyre is a former associate professor anesthesiologist and intensive care specialist from Paris and has more than 20 years experience working in Clinical Development, Medical Affairs and Pharmacovigilance/Risk Management for international big pharm…more ›

Ragnar E.Lofstedt is Professor of Risk Management and the Director of King’s Centre of Risk Management, King’s College London, UK where he teaches and conducts research on risk communication and management. Previously he was a Reader in Social Geography at the Universi…more ›

Véronique Basch, PharmD, is the Executive Director, Pharmacovigilance for United BioSource Corporation and is based in Geneva, Switzerland. She manages the development, implementation, and execution of UBC’s safety strategy, providing direction, oversight, and mana…more ›

Dr Ennis Lee qualified from Westminster Medical School and practised in the NHS in general medicine and medical oncology. Dr Lee joined the pharmaceutical industry over 25 years ago and has worked for several major pharmaceutical companies, in all phases of drug devel…more ›

Dr. Rahman is currently a Senior Director & Clinical Risk Management Group Leader in the Global Safety Department at Merck & Co., Inc. He is also a practicing physician at the Concentra Occupational Medicine & Urgent Care Medical Centers, and is a volunteer …more ›